 Mark Eckardt
Concepts (216)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma | 9 | 2025 | 193 | 1.770 |
Why?
| | Liposarcoma | 4 | 2023 | 30 | 1.250 |
Why?
| | Soft Tissue Neoplasms | 4 | 2025 | 120 | 1.160 |
Why?
| | Psoriasis | 2 | 2024 | 112 | 0.930 |
Why?
| | Mindfulness | 2 | 2024 | 149 | 0.840 |
Why?
| | Doxorubicin | 9 | 2018 | 369 | 0.790 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2022 | 22 | 0.780 |
Why?
| | Carbon-Sulfur Lyases | 6 | 2018 | 14 | 0.740 |
Why?
| | Xenograft Model Antitumor Assays | 9 | 2018 | 917 | 0.650 |
Why?
| | Referral and Consultation | 1 | 2025 | 802 | 0.620 |
Why?
| | Salmonella typhimurium | 5 | 2018 | 189 | 0.530 |
Why?
| | Antimetabolites, Antineoplastic | 2 | 2018 | 95 | 0.410 |
Why?
| | Radiodermatitis | 1 | 2013 | 11 | 0.400 |
Why?
| | Deoxycytidine | 2 | 2018 | 202 | 0.390 |
Why?
| | Compartment Syndromes | 1 | 2013 | 34 | 0.380 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2011 | 27 | 0.360 |
Why?
| | Philadelphia Chromosome | 1 | 2011 | 19 | 0.360 |
Why?
| | Sarcoma, Ewing | 3 | 2018 | 100 | 0.360 |
Why?
| | Blast Crisis | 1 | 2011 | 34 | 0.360 |
Why?
| | Hemangioendothelioma, Epithelioid | 1 | 2011 | 7 | 0.360 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2018 | 840 | 0.350 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2011 | 75 | 0.350 |
Why?
| | Thiazoles | 1 | 2011 | 133 | 0.340 |
Why?
| | Mice, Nude | 11 | 2018 | 700 | 0.330 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2011 | 125 | 0.330 |
Why?
| | Pyrimidines | 3 | 2018 | 510 | 0.330 |
Why?
| | Nerve Sheath Neoplasms | 2 | 2019 | 13 | 0.310 |
Why?
| | Recombinant Proteins | 5 | 2018 | 1362 | 0.310 |
Why?
| | Image-Guided Biopsy | 2 | 2019 | 41 | 0.260 |
Why?
| | Bone Matrix | 2 | 2018 | 8 | 0.260 |
Why?
| | Melanoma | 3 | 2018 | 786 | 0.260 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2022 | 1075 | 0.240 |
Why?
| | Sphincterotomy, Transduodenal | 1 | 2025 | 2 | 0.230 |
Why?
| | Piperazines | 3 | 2018 | 375 | 0.230 |
Why?
| | Ampulla of Vater | 1 | 2025 | 36 | 0.220 |
Why?
| | Cyclin-Dependent Kinase 4 | 2 | 2016 | 48 | 0.220 |
Why?
| | Cyclin-Dependent Kinase 6 | 2 | 2016 | 42 | 0.220 |
Why?
| | Lumbar Vertebrae | 2 | 2018 | 252 | 0.220 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 1791 | 0.210 |
Why?
| | Pyridines | 3 | 2018 | 560 | 0.210 |
Why?
| | Gastric Bypass | 1 | 2025 | 119 | 0.200 |
Why?
| | Spinal Fusion | 2 | 2018 | 260 | 0.200 |
Why?
| | Lipoma | 1 | 2023 | 17 | 0.200 |
Why?
| | Robotic Surgical Procedures | 1 | 2025 | 151 | 0.190 |
Why?
| | Humans | 34 | 2025 | 141284 | 0.190 |
Why?
| | Bone Marrow Transplantation | 2 | 2015 | 292 | 0.190 |
Why?
| | Retrospective Studies | 9 | 2025 | 16447 | 0.180 |
Why?
| | Microsatellite Instability | 1 | 2022 | 49 | 0.180 |
Why?
| | Bone Neoplasms | 2 | 2016 | 249 | 0.180 |
Why?
| | Antineoplastic Agents | 3 | 2018 | 2162 | 0.170 |
Why?
| | Salmonella Infections | 2 | 2018 | 56 | 0.170 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2021 | 112 | 0.170 |
Why?
| | Gastrointestinal Stromal Tumors | 1 | 2021 | 39 | 0.160 |
Why?
| | Adolescent | 8 | 2025 | 22116 | 0.160 |
Why?
| | Biopsy, Large-Core Needle | 1 | 2019 | 15 | 0.160 |
Why?
| | Colorectal Neoplasms | 2 | 2022 | 811 | 0.150 |
Why?
| | Neoadjuvant Therapy | 2 | 2020 | 429 | 0.150 |
Why?
| | Self Report | 1 | 2024 | 859 | 0.150 |
Why?
| | Cisplatin | 2 | 2018 | 328 | 0.150 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2018 | 225 | 0.150 |
Why?
| | Lipopolysaccharides | 1 | 2022 | 854 | 0.150 |
Why?
| | Fibrosarcoma | 1 | 2018 | 21 | 0.150 |
Why?
| | Bone Demineralization Technique | 1 | 2018 | 1 | 0.140 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2018 | 45 | 0.140 |
Why?
| | Pseudomonas putida | 1 | 2018 | 39 | 0.130 |
Why?
| | Furans | 1 | 2017 | 25 | 0.130 |
Why?
| | Osteosarcoma | 1 | 2018 | 73 | 0.130 |
Why?
| | Aged | 10 | 2025 | 24836 | 0.130 |
Why?
| | Ketones | 1 | 2017 | 52 | 0.130 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2016 | 16 | 0.130 |
Why?
| | RNA-Binding Protein FUS | 1 | 2016 | 14 | 0.120 |
Why?
| | Combined Modality Therapy | 3 | 2018 | 1243 | 0.120 |
Why?
| | Cell Tracking | 1 | 2016 | 17 | 0.120 |
Why?
| | Receptor, IGF Type 1 | 1 | 2016 | 63 | 0.120 |
Why?
| | Bone Marrow | 1 | 2018 | 298 | 0.120 |
Why?
| | Tumor Microenvironment | 1 | 2021 | 711 | 0.120 |
Why?
| | Female | 16 | 2025 | 75814 | 0.120 |
Why?
| | Immunotherapy | 1 | 2021 | 641 | 0.120 |
Why?
| | Neoplasms, Experimental | 1 | 2016 | 174 | 0.120 |
Why?
| | Luminescent Proteins | 1 | 2016 | 182 | 0.120 |
Why?
| | Male | 15 | 2025 | 70140 | 0.110 |
Why?
| | Prognosis | 5 | 2025 | 4080 | 0.110 |
Why?
| | Middle Aged | 9 | 2025 | 34658 | 0.110 |
Why?
| | Postoperative Complications | 2 | 2025 | 2831 | 0.110 |
Why?
| | Bone Transplantation | 1 | 2015 | 90 | 0.110 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2016 | 205 | 0.110 |
Why?
| | Depression | 1 | 2024 | 1490 | 0.110 |
Why?
| | Precision Medicine | 1 | 2018 | 435 | 0.100 |
Why?
| | Body Weight | 4 | 2018 | 992 | 0.100 |
Why?
| | Aurora Kinase A | 1 | 2013 | 56 | 0.100 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 420 | 0.100 |
Why?
| | Young Adult | 4 | 2025 | 13727 | 0.100 |
Why?
| | Prospective Studies | 2 | 2022 | 7805 | 0.100 |
Why?
| | Musculoskeletal Diseases | 1 | 2014 | 87 | 0.100 |
Why?
| | Sarcoma, Synovial | 1 | 2013 | 22 | 0.100 |
Why?
| | Random Allocation | 3 | 2018 | 369 | 0.100 |
Why?
| | Phthalazines | 1 | 2013 | 63 | 0.100 |
Why?
| | Tumor Burden | 3 | 2018 | 314 | 0.090 |
Why?
| | Animals | 13 | 2018 | 37328 | 0.090 |
Why?
| | Giant Cell Tumor of Bone | 1 | 2012 | 7 | 0.090 |
Why?
| | Curettage | 1 | 2012 | 9 | 0.090 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1996 | 0.090 |
Why?
| | Dasatinib | 1 | 2011 | 57 | 0.090 |
Why?
| | Surveys and Questionnaires | 1 | 2024 | 5948 | 0.090 |
Why?
| | Fatal Outcome | 1 | 2011 | 309 | 0.080 |
Why?
| | Adult | 7 | 2025 | 39319 | 0.080 |
Why?
| | Tibia | 1 | 2012 | 182 | 0.080 |
Why?
| | Mice | 8 | 2018 | 17969 | 0.080 |
Why?
| | Survival Analysis | 3 | 2019 | 1322 | 0.080 |
Why?
| | Databases, Factual | 3 | 2020 | 1449 | 0.080 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2013 | 528 | 0.080 |
Why?
| | Mutation | 2 | 2018 | 4006 | 0.070 |
Why?
| | Fatty Liver | 1 | 2011 | 237 | 0.070 |
Why?
| | Indazoles | 2 | 2018 | 77 | 0.070 |
Why?
| | Lung Neoplasms | 2 | 2018 | 2554 | 0.060 |
Why?
| | Green Fluorescent Proteins | 2 | 2018 | 403 | 0.060 |
Why?
| | Tumor Cells, Cultured | 2 | 2018 | 959 | 0.060 |
Why?
| | Administration, Oral | 2 | 2018 | 825 | 0.060 |
Why?
| | Liver Neoplasms | 1 | 2011 | 741 | 0.060 |
Why?
| | Constriction, Pathologic | 1 | 2025 | 242 | 0.050 |
Why?
| | Sulfonamides | 2 | 2018 | 576 | 0.050 |
Why?
| | Cell Proliferation | 3 | 2018 | 2502 | 0.050 |
Why?
| | Mitotic Index | 1 | 2023 | 25 | 0.050 |
Why?
| | Disease Models, Animal | 3 | 2018 | 4414 | 0.050 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2013 | 195 | 0.050 |
Why?
| | Neoplasms | 1 | 2018 | 2731 | 0.050 |
Why?
| | Treatment Outcome | 4 | 2018 | 11216 | 0.050 |
Why?
| | DNA Mismatch Repair | 1 | 2022 | 48 | 0.050 |
Why?
| | Mitosis | 1 | 2023 | 198 | 0.050 |
Why?
| | Neoplasm Staging | 2 | 2019 | 1397 | 0.040 |
Why?
| | Imatinib Mesylate | 1 | 2021 | 80 | 0.040 |
Why?
| | Radiopharmaceuticals | 1 | 2021 | 189 | 0.040 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2021 | 149 | 0.040 |
Why?
| | Cell Cycle | 2 | 2013 | 601 | 0.040 |
Why?
| | Germany | 1 | 2020 | 132 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2021 | 309 | 0.040 |
Why?
| | Neurofibroma | 1 | 2019 | 5 | 0.040 |
Why?
| | Risk Assessment | 2 | 2019 | 3522 | 0.040 |
Why?
| | Neurilemmoma | 1 | 2019 | 24 | 0.040 |
Why?
| | Hospitals, High-Volume | 1 | 2019 | 45 | 0.040 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 383 | 0.040 |
Why?
| | Age Factors | 2 | 2018 | 3295 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 1 | 2011 | 3734 | 0.040 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 211 | 0.040 |
Why?
| | Cohort Studies | 2 | 2019 | 5809 | 0.040 |
Why?
| | S Phase Cell Cycle Checkpoints | 1 | 2018 | 5 | 0.040 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2018 | 45 | 0.040 |
Why?
| | Empathy | 1 | 2020 | 176 | 0.030 |
Why?
| | Gene Amplification | 1 | 2018 | 105 | 0.030 |
Why?
| | Suction | 1 | 2018 | 34 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2018 | 194 | 0.030 |
Why?
| | Artificial Intelligence | 1 | 2022 | 342 | 0.030 |
Why?
| | Taxoids | 1 | 2018 | 105 | 0.030 |
Why?
| | Injections, Intraperitoneal | 1 | 2017 | 115 | 0.030 |
Why?
| | California | 1 | 2019 | 457 | 0.030 |
Why?
| | Heterografts | 1 | 2018 | 135 | 0.030 |
Why?
| | Point Mutation | 1 | 2018 | 239 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2019 | 510 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 713 | 0.030 |
Why?
| | Early Detection of Cancer | 1 | 2022 | 432 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2017 | 168 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 910 | 0.030 |
Why?
| | Orthopedic Procedures | 1 | 2019 | 231 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 75 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2019 | 523 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1268 | 0.030 |
Why?
| | Pyrazines | 1 | 2016 | 88 | 0.030 |
Why?
| | Ilium | 1 | 2015 | 30 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2013 | 3502 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2017 | 771 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1505 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1491 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 1043 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 2018 | 361 | 0.030 |
Why?
| | Imidazoles | 1 | 2016 | 251 | 0.030 |
Why?
| | Reoperation | 1 | 2018 | 599 | 0.030 |
Why?
| | Apoptosis | 2 | 2013 | 2487 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 1973 | 0.030 |
Why?
| | Allografts | 1 | 2015 | 148 | 0.030 |
Why?
| | Transplantation, Autologous | 1 | 2015 | 282 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2015 | 411 | 0.030 |
Why?
| | Aurora Kinase C | 1 | 2013 | 1 | 0.030 |
Why?
| | Aurora Kinase B | 1 | 2013 | 11 | 0.030 |
Why?
| | Biopsy, Needle | 1 | 2014 | 189 | 0.030 |
Why?
| | Retinoblastoma Protein | 1 | 2013 | 60 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2013 | 123 | 0.020 |
Why?
| | DNA Copy Number Variations | 1 | 2013 | 178 | 0.020 |
Why?
| | DNA Mutational Analysis | 1 | 2013 | 396 | 0.020 |
Why?
| | Femoral Neoplasms | 1 | 2012 | 10 | 0.020 |
Why?
| | Radius | 1 | 2012 | 52 | 0.020 |
Why?
| | Organoplatinum Compounds | 1 | 2011 | 50 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2018 | 911 | 0.020 |
Why?
| | Liver Function Tests | 1 | 2011 | 106 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2015 | 7948 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2016 | 2165 | 0.020 |
Why?
| | Carcinoma, Renal Cell | 1 | 2013 | 221 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 4180 | 0.020 |
Why?
| | Logistic Models | 1 | 2015 | 2098 | 0.020 |
Why?
| | Kidney Neoplasms | 1 | 2013 | 400 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2013 | 2047 | 0.020 |
Why?
| | Phosphorylation | 1 | 2013 | 1753 | 0.020 |
Why?
| | Gene Expression | 1 | 2013 | 1490 | 0.020 |
Why?
| | Quality of Life | 1 | 2020 | 3024 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2013 | 918 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2013 | 1439 | 0.020 |
Why?
| | Biomarkers, Tumor | 1 | 2013 | 1250 | 0.020 |
Why?
| | Sex Factors | 1 | 2011 | 2055 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2014 | 5222 | 0.010 |
Why?
| | Liver | 1 | 2011 | 1821 | 0.010 |
Why?
| | Child | 2 | 2014 | 22390 | 0.010 |
Why?
| | Body Mass Index | 1 | 2011 | 2390 | 0.010 |
Why?
| | United States | 1 | 2020 | 15298 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2246 | 0.010 |
Why?
| | Infant | 1 | 2014 | 9820 | 0.010 |
Why?
| | Child, Preschool | 1 | 2014 | 11511 | 0.010 |
Why?
| | Risk Factors | 1 | 2011 | 10490 | 0.010 |
Why?
|
|
Eckardt's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|